2019 CICON年会,Kymab公布其诱导型T细胞共刺激物ICOS单抗的积极新发现

2019-09-27 不详 MedSci原创

在2019年第五届CRI-CIMT-EATI-AACR国际癌症免疫治疗会议(CICON)上,Kymab宣布其诱导型T细胞共刺激物(ICOS)单抗KY1044的研究进展,该新型单抗与ICOS结合以消耗肿瘤内调节性T细胞并刺激效应T细胞,从而促进针对肿瘤的免疫反应。

在2019年第五届CRI-CIMT-EATI-AACR国际癌症免疫治疗会议(CICON)上,Kymab宣布其诱导型T细胞共刺激物(ICOS)单抗KY1044的研究进展,该新型单抗与ICOS结合以消耗肿瘤内调节性T细胞并刺激效应T细胞,从而促进针对肿瘤的免疫反应。

CICON海报中提供的数据表明,KY1044 通过抗体依赖性细胞毒性(ADCC)以剂量依赖性方式杀死了ICOS高表达的调节性T细胞,并保留了ICOS低表达的效应T细胞。通过消耗调节性T细胞,KY1044单药治疗以及与抗PD?L1组合可强烈抑制肿瘤生长。KY1044还充当ICOS 低效应T细胞的共刺激激动剂抗体,并在体外和体内诱导效应T细胞增加炎症细胞因子表达。这些数据表明,KY1044可提高效应T细胞与调节性T细胞的比例。

在美国、英国和意大利,一项正在进行的1/2期、开放标签、多中心研究评估了KY1044作为单一药物并与抗PD-L1(atezolizumab)联合治疗在某些晚期恶性肿瘤成年患者中的安全性和有效性(NCT03829501)。

ICOS在T细胞上激活后表达,并在大多数FOXP3+CD4+调节性T细胞上高水平表达。现有数据表明,从肿瘤微环境中清除这些免疫抑制细胞可能会增强患者的抗肿瘤免疫反应。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912220, encodeId=4224191222006, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 06 15:36:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970972, encodeId=187019e0972ab, content=<a href='/topic/show?id=f1929364cb' target=_blank style='color:#2F92EE;'>#ICOS单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9364, encryptionId=f1929364cb, topicName=ICOS单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri May 22 00:36:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921259, encodeId=36b81921259a8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri May 29 16:36:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005567, encodeId=f4c5200556ed8, content=<a href='/topic/show?id=a2344e026f' target=_blank style='color:#2F92EE;'>#CICON#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4702, encryptionId=a2344e026f, topicName=CICON)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Oct 10 06:36:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373275, encodeId=7b843e3275bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:33 CST 2019, time=2019-09-27, status=1, ipAttribution=)]
    2020-04-06 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912220, encodeId=4224191222006, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 06 15:36:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970972, encodeId=187019e0972ab, content=<a href='/topic/show?id=f1929364cb' target=_blank style='color:#2F92EE;'>#ICOS单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9364, encryptionId=f1929364cb, topicName=ICOS单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri May 22 00:36:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921259, encodeId=36b81921259a8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri May 29 16:36:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005567, encodeId=f4c5200556ed8, content=<a href='/topic/show?id=a2344e026f' target=_blank style='color:#2F92EE;'>#CICON#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4702, encryptionId=a2344e026f, topicName=CICON)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Oct 10 06:36:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373275, encodeId=7b843e3275bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:33 CST 2019, time=2019-09-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1912220, encodeId=4224191222006, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 06 15:36:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970972, encodeId=187019e0972ab, content=<a href='/topic/show?id=f1929364cb' target=_blank style='color:#2F92EE;'>#ICOS单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9364, encryptionId=f1929364cb, topicName=ICOS单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri May 22 00:36:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921259, encodeId=36b81921259a8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri May 29 16:36:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005567, encodeId=f4c5200556ed8, content=<a href='/topic/show?id=a2344e026f' target=_blank style='color:#2F92EE;'>#CICON#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4702, encryptionId=a2344e026f, topicName=CICON)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Oct 10 06:36:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373275, encodeId=7b843e3275bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:33 CST 2019, time=2019-09-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1912220, encodeId=4224191222006, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 06 15:36:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970972, encodeId=187019e0972ab, content=<a href='/topic/show?id=f1929364cb' target=_blank style='color:#2F92EE;'>#ICOS单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9364, encryptionId=f1929364cb, topicName=ICOS单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri May 22 00:36:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921259, encodeId=36b81921259a8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri May 29 16:36:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005567, encodeId=f4c5200556ed8, content=<a href='/topic/show?id=a2344e026f' target=_blank style='color:#2F92EE;'>#CICON#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4702, encryptionId=a2344e026f, topicName=CICON)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Oct 10 06:36:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373275, encodeId=7b843e3275bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:33 CST 2019, time=2019-09-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1912220, encodeId=4224191222006, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Apr 06 15:36:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970972, encodeId=187019e0972ab, content=<a href='/topic/show?id=f1929364cb' target=_blank style='color:#2F92EE;'>#ICOS单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9364, encryptionId=f1929364cb, topicName=ICOS单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri May 22 00:36:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921259, encodeId=36b81921259a8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri May 29 16:36:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005567, encodeId=f4c5200556ed8, content=<a href='/topic/show?id=a2344e026f' target=_blank style='color:#2F92EE;'>#CICON#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4702, encryptionId=a2344e026f, topicName=CICON)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Oct 10 06:36:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373275, encodeId=7b843e3275bc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:33 CST 2019, time=2019-09-27, status=1, ipAttribution=)]
    2019-09-27 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

2019 CSCO:多项重磅研究成果发布,引领肿瘤个体化医疗新时代

此次价格联动范围包括,山东省平台挂网产品中除国家和省已有明确规定的药品(如国家谈判、定点生产、基础输液、短缺药品等)外所有挂网药品(含平台内“药品挂网目录管理”、“药品备选目录”中全部产品、开通点对点医疗机构交易的屏蔽产品)。 山东表示,药品挂网

2019 ASBMR:硬化蛋白单抗Setrusumab在成骨不全症方面有治疗潜力

在2019年美国骨与矿物质学会(ASBMR)年会上发表的一项研究显示,一种靶向于硬化蛋白的全人源IgG2型单克隆抗体Setrusumab显示出治疗成骨不全症(OI)的潜力。

2019 ASBMR:服用高剂量的维生素D与动脉钙化无关

佛罗里达州奥兰多市举办的2019年美国骨与矿物质研究学会(ASBMR)年会上进行的次要分析显示,无论维生素D的剂量如何,健康的中年男女都不会发生血管钙化。

2019 ESMO:罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

在2019年欧洲医学肿瘤学会(ESMO)大会上,罗氏公布将血管内皮生长因子单抗Avastin(贝伐单抗)与PD-L1单抗Tecentriq(atezolizumab)联合在未接受过全身治疗、不可切除的肝细胞癌(HCC)(最常见的肝癌形式)患者中Ib期临床的疗效和安全性研究结果。

陈荣昌教授:中国在慢性阻塞性肺疾病研究中的贡献和探索:CTS 2019

9月6号中华医学会呼吸病学年会上,中华医学会呼吸病学分会第十届委员会主委、慢阻肺学组组长、深圳市人民医院深圳呼吸疾病研究所所长陈荣昌教授针对中国在慢性阻塞性肺疾病研究中的贡献和探索做了一场专题报告,下面小编为您整理送上。我国慢阻肺的疾病负担与特点呼吸疾病(包括肺癌)是中国第一疾病负担,40岁及以上人群慢阻肺患病率已超过13%。我国慢阻肺人群特征存在多样性,包括社区流行病学调查发现的人群、症状驱

2019 ESPE:循环miR-451a可能用作青少年多囊卵巢综合症诊断的生物标志物

在奥地利维也纳召开的第58届欧洲小儿内分泌学会(ESPE)年会的一项研究显示,多囊卵巢综合症(PCOS)青少年的循环miR-451a浓度明显降低,有可能用于该疾病的诊断。该发现很重要,因为目前尚无明确诊断PCOS的标志物。